Journals / Turkish Journal of Surgery / 2017 / Cilt: 33 - Sayı: 4

Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases

Pages
279–283
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, we believe that collecting regular national data from these cases in every country will contribute to understanding the details of this entity worldwide

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Neuroendocrine tumors arise from neuroendocrine cells in any part of the body; approximately two thirds of these tumors are located in the gastrointestinal tract and pancreas.
📊
Key Findings & Data:Although gastroenteropancreatic neuroendocrine tumors are known as rare neoplasms, their prevalence has recently increased due to advanced diagnostic methods and increased awareness of the disorder.
💡
Conclusion & Impact:Therefore, we believe that collecting regular national data from these cases in every country will contribute to understanding the details of this entity worldwide
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Neuroendocrine tumors arise from neuroendocrine cells in any part of the body; approximately two thirds of these tumors are located in the gastrointestinal tract and pancreas. Although gastroenteropancreatic neuroendocrine tumors are known as rare neoplasms, their prevalence has recently increased due to advanced diagnostic methods and increased awareness of the disorder. In the present study, we aimed to review patients who were treated and followed up for gastroenteropancreatic neuroendocrine tumors at our clinic in terms of clinical picture, pathological findings, and prognosis. Material and Methods: Data from 42 patients diagnosed with gastroenteropancreatic neuroendocrine tumors who were treated and followed up at our Training and Research Hospital from August 2011 to December 2015 were retrospectively evaluated.Results: A total of 42 patients aged 17-81 years (mean age 46.9 years) were enrolled in the study. The most common symptom was abdominal pain, which was seen in 31 (73.8%) patients. gastroenteropancreatic neuroendocrine tumors were detected in the stomach (n=5, 35.7%), appendix (n=11, 26.2%), rectum (n=6, 14.3%), pancreas (n=4, 9.5%), ileum and colon (n=2, 4.8%), and duodenum and jejunum (n=1, 2.4%). Local excision was performed in seven (16.7%) patients. Nine (21.4%) patients underwent gastric wedge resections, either by a laparoscopic procedure (n=3) or by open surgery (n=6). Total gastrectomy and laparoscopic subtotal gastrectomy were performed on three (7.1%) patients and two patients (4.8%), respectively. After the surgical procedures, the patients were followed up for a mean period of 36 months (15-57 months); the one-year and three-year survival rates were determined to be 100% and 97.6%, respectively. Conclusion: Management of gastroenteropancreatic neuroendocrine tumors requires accumulation of knowledge and experience to establish a standardized approach. Therefore, we believe that collecting regular national data from these cases in every country will contribute to understanding the details of this entity worldwide

🔖

Cite This Article

BÜYÜKAŞIK, K., ARI, A., TATAR, C., AKÇE, B., SEVİNÇ, M. M., SARI, S., PAŞAOĞLU, E., BEKTAŞ, H. (2017). Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases. Turkish Journal of Surgery, Cilt: 33 - Sayı: 4, 279–283. https://ajindex.com/articles/390508

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic euroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr Relat Cancer 2010
  2. [CrossRef] 2. Serin KR, Keskin M, Gulluoglu M, Emre A. Atypical localisation of a gastrointestinal stromal tumour: a case report of pancreas gastrointestinal stromal tumour. Turk J Surg 2013
  3. [CrossRef] 3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008
  4. [CrossRef] 4. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011
  5. [CrossRef] 5. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011
  6. [CrossRef] 6. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Geneva, Switzerland: World Health Organization 2010. 7. Rindi G, Klöppel G, Alhman H. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006
  7. [CrossRef] 8. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas 2010
  8. [CrossRef] 9. Zhang X, Ma L, Bao H. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord 2014
  9. [CrossRef] 10. Diez M, Teule A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol 2013
  10. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008
  11. [CrossRef] 12. Modlin IM, Moss SF, Gustafsson BI. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg 2011
  12. [CrossRef] 13. Guven K. MRI, CT and FDG/PET/CT for diagnosis and follow-up of Gastroenteropancreatic Neuroendocrine tumors. Turkiye Klinikleri J Med Oncol-Spe